Takeda Pharmaceutical Company Ltd

AI revolutionizes clinical trials by enhancing data collection, patient recruitment, and analysis, reducing time and costs. It enables personalized medicine, improves efficiency, and accelerates drug development. Despite challenges like data quality and ethical concerns, AI's potential in clinical trials is transformative, promising faster, more accurate outcomes.

Shane Ryan, new IPHA president, emphasizes partnership to foster innovation and improve health outcomes in Ireland's biopharmaceutical sector, urging industry and government to avoid complacency. With a general election looming, the IPHA's manifesto calls for faster access to new medicines and increased clinical trials, aiming to make Ireland a life sciences investment destination.

DPHARM 2024 featured a session on improving patient recruitment outcomes with Jill Pellegrino, CEO of AutoCruitment. A study found women with asthma more likely to need fertility treatments and experience higher miscarriage rates. A special report explores future food trends, including robots in kitchens and algae-based cooking oil. Takeda committed $32 million to five global CSR partners to enhance health systems in low and middle-income countries. Rob Verheul seeks success and failure stories on personalization in digital pharma.

DPHARM panel discussed innovations needed to address clinical trial challenges in resource-constrained environments, emphasizing collaboration, data-driven decisions, and leveraging digital solutions. Key points included optimizing trial operations, regulatory engagement, and financial efficiency, with a focus on patient-centric and automated approaches.

Ipsen’s Phase III CONTACT-02 trial of Cabometyx with Roche’s Tecentriq in mCRPC failed to meet OS improvement at 24 months, leading to no regulatory submissions for the combo therapy. Despite this, Exelixis plans to submit a supplemental new drug application to the FDA for the combo in mCRPC.

The article discusses the importance of SSR (Server-Side Rendering) in web development for improving performance and SEO.

R.A.S., M.S.T., C.Y., R.N., H.S.R., M.D., A.J.C., E.S.-R., J.C.B., C.O., K.K., A.D.E., C.V., N.W., K.S.A., A.S.C., C.F., C.I., A.T., J.T., K.Y., L.H., K.G., F.M.H., T.S., A.L.A., P.B., P.N., G.L.H., W.F.S., J.P., P.P., A.D.M., D.Y., L.J.v.V., N.M.H., L.J.E. report various institutional research funding, advisory roles, consultancy, honoraria, patents, and stock ownership.

FDA approves Roche's OCREVUS ZUNOVO™ with Halozyme's ENHANZE® for RMS and PPMS, offering a 10-minute subcutaneous injection.

Roche received FDA approval for OCREVUS ZUNOVO™, a subcutaneous injection using Halozyme's ENHANZE® technology for RMS and PPMS, offering a 10-minute, twice-a-year treatment.

Neurocrine Biosciences halts development of schizophrenia drug luvadaxistat after ERUDITE Phase II trial fails to replicate cognitive improvements seen in INTERACT study, attributing failure to variability in cognitive measures and baseline imbalances. The company will focus on other neuropsychiatric assets.